PUBLIC COMPANY
saveBaxalta Inc
updated 1mo ago
Baxalta is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. The company began its operation with a revenue of $6 billion, and is now a subsidiary of Takeda Pharmaceutical Company.
community read0 votes
pipeline
7
marketed
7
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(7)
pipeline depth7 products
7Marketed
Marketed
(hyaluronidase (recombinant, human) + immune globulin (human))
Primary Immune Deficiency (PID)
Marketedanti-inhibitor coagulant complex
Hemophilia A (Factor VIII Deficiency)
Marketedantihemophilic factor (recombinant), pegylated LA
Hemophilia A (Factor VIII Deficiency)
Marketedantihemophilic factor (recombinant), plasma/albumin free method
Hemophilia A (Factor VIII Deficiency)
Marketedantihemophilic factor (recombinant), porcine sequence
Acquired Hemophilia A
Marketedprotein C concentrate (human)
Venous (Vein) Thrombosis
Marketedvon willebrand factor (recombinant)
Von Willebrand Disease (vWD)
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
no news has mentioned this company yet
comments(0)
5-min edit window · permanent after that